Where does Suturegard Medical Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Suturegard Medical Inc. ranks #30,299 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Suturegard Medical Inc. hold?

Suturegard Medical Inc. holds 9 US utility patents granted between 2019 and 2025, spanning 2 technology areas.

What is Suturegard Medical Inc.'s Innovation Score?

Suturegard Medical Inc. has an Innovation Score of 24.3 out of 100 (14th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Suturegard Medical Inc. focus on?

Suturegard Medical Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 7 patents, ranking #2,341 of 7,127 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

Is Suturegard Medical Inc.'s patent grant rate increasing or decreasing?

Suturegard Medical Inc.'s recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Suturegard Medical Inc.'s patents?

Suturegard Medical Inc.'s patents average 12.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Suturegard Medical Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Suturegard Medical Inc.

USPTO PatentsView assignee record - 9 granted patents across 2 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Suturegard ranks #30,299 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 2 technology areas.

#30,299
of 49,997 US assignees by volume: 14th percentile
by Innovation Score (24.3/100): 12.2
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30299 · US Corporation #30,299 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #30,299/49,997
PHOTO-FINISH Sunshine Guojian…
CPC-NARROW A61B · 2 areas
INNOV-THIN 24.3/100
CLAIMS-RICH 12.2 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sunshine Guojian Pharmaceutical (SHANGHAI) Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Suturegard’s 24.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (33%) Velocity 4.0 pts (16%) Breadth 5.0 pts (21%) Claim depth 7.3 pts (30%)

Qualcomm Incorporated · highest

85
Suturegard Medical · this assignee

24
3D Lighting… · lowest

7

What this shows Suturegard's Innovation Score is 24.3/100 (14th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Suturegard?

Each dot is one of Suturegard’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Suturegard’s own 12.2 claims/patent is ABOVE the 11.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Suturegard vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Suturegard's grants concentrate

Suturegard Medical Inc. is a focused PatentsView assignee: 2 CPC subclasses with 77.8% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2020 (3 grants) versus a trough of 2 in 2019. By volume, Suturegard sits between Sunshine Guojian Pharmaceutical (SHANGHAI) Co., Ltd. and Synbio Tech Inc..

Suturegard's three-year grant acceleration

Suturegard Medical Inc. shows 3 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Sunshine Guojian…

9
Suntec

9
Super HI FI

9
Superior Transmis…

9
Swell Industries

9
Swic

9
Sylentis SAU

9
Synbio Tech

9
Suturegard Medical ◀

9

What this shows Suturegard holds 9 patents at rank #30,115, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Suturegard

By rank, the assignees closest to #30,115 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Suturegard's primary technology class.

Suturegard's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 14th percentile higher than 14% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Suturegard Medical Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	22.2%
2020	3	33.3%
2023	3	33.3%
2025partial year	1	11.1%

Which technologies does Suturegard Medical Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 7

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Suturegard Medical Inc.'s patent record in context - here's where to go next.

Suturegard Medical Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 77.8% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #30,299 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Suturegard Medical Inc. against Sunshine Guojian Pharmaceutical (SHANGHAI) Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.